( NASDAQ-NMS:MYL )

News from Mylan Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

09 Feb, 2015, 11:45 ET Mylan Schedules Fourth Quarter and Year End 2014 Financial Results Conference Call and Live Webcast

Mylan Inc. (Nasdaq: MYL) announced today that it will host a conference call and live webcast, including a slide presentation, on Monday, March 2,...


09 Feb, 2015, 11:00 ET Mylan Confirms First-to-File Patent Challenge Relating to NEXAVAR®

 Mylan Inc. (Nasdaq: MYL) today confirmed that it and its subsidiary Mylan Pharmaceuticals have been sued by Bayer Healthcare LLC, Bayer...


02 Feb, 2015, 07:00 ET Theravance Biopharma, Inc. and Mylan Partner to Develop and Commercialize a Novel LAMA Compound, TD-4208, for COPD

 Theravance Biopharma, Inc. (NASDAQ: TBPH) and Mylan Inc. (NASDAQ: MYL) today announced that the two companies will partner on the development...


02 Feb, 2015, 06:44 ET Mylan to Acquire Famy Care Businesses to Create a Leading Women's Health Care Franchise

 Mylan Inc. (Nasdaq: MYL) today announced that it has, through its Indian subsidiary Mylan Laboratories Limited, signed a definitive agreement...


29 Jan, 2015, 11:18 ET Mylan Shareholders Overwhelmingly Approve Agreement Implementing Acquisition of Abbott's Non-U.S. Developed Markets Specialty and Branded Generics Business

 Mylan Inc. (Nasdaq: MYL) announced that at a Special Meeting of Shareholders held Jan. 29, 2015, Mylan's shareholders overwhelmingly...


26 Jan, 2015, 10:58 ET Mylan Expands Hepatitis C Licensing Agreement with Gilead to Include Investigational Pan-Genotypic Agent

 Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited is expanding its hepatitis C licensing agreement with...


20 Jan, 2015, 12:51 ET U.S. Supreme Court Partially Modifies Standard of Review of Patent Claim Construction and Remands Review of Teva's '808 Patent on Copaxone® to Federal Circuit Court of Appeals

 Mylan Inc. (Nasdaq: MYL) today announced that the U.S. Supreme Court has partially modified the standard of review to be applied by the U.S....


15 Jan, 2015, 14:29 ET Mylan Launches Generic Epivir-HBV® Tablets

 Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Lamivudine Tablets, 100 mg, which is the generic version of GlaxoSmithKline's...


05 Jan, 2015, 13:00 ET Mylan Launches Generic Diovan® Tablets

 Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Valsartan Tablets USP 40 mg, 80 mg, 160 mg, and 320 mg, which is the...


31 Dec, 2014, 06:00 ET South African National Department of Health Selects Mylan as a Leading Supplier for 2015/2018 Antiretroviral Tender

 Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary in India, Mylan Laboratories Ltd., a leading manufacturer of antiretroviral...


22 Dec, 2014, 07:30 ET Mylan Launches First Generic Version of Vivelle-DOT®

 Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Estradiol Transdermal System USP, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day,...


17 Dec, 2014, 09:00 ET Mylan to Present at the J.P. Morgan 33rd Annual Healthcare Conference

 Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that the Company will...


11 Dec, 2014, 07:30 ET Mylan Launches Generic Robaxin® Injection

 Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL...


11 Dec, 2014, 07:00 ET Mylan Launches First Generic Version of Orapred ODT®

Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg, and 30...


10 Dec, 2014, 07:30 ET Mylan Launches One of First Available Generic Versions of Celebrex® Capsules

 Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first...


08 Dec, 2014, 05:01 ET World TeamTennis and Mylan Announce Title Sponsorship Extension Through 2017

 World TeamTennis (WTT), the innovative leader in professional team tennis competition, and Mylan (Nasdaq: MYL), one of the world's leading...


04 Dec, 2014, 10:00 ET Mylan receives tentative FDA approval for pediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative

 Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and...


01 Dec, 2014, 21:00 ET Mylan and Canadian AIDS Society Team up in Cross-Country Relay to Accelerate Canada's Fight Against HIV/AIDS

OTTAWA, Dec. 1, 2014 /CNW Telbec/ - Mylan Inc. (Nasdaq: MYL) and the Canadian AIDS Society (CAS) today announced a joint initiative to raise funds...


01 Dec, 2014, 21:00 ET Mylan and Canadian AIDS Society Team up in Cross-Country Relay to Accelerate Canada's Fight Against HIV/AIDS

Mylan Inc. (Nasdaq: MYL) and the Canadian AIDS Society (CAS) today announced a joint initiative to raise funds and awareness for Canadians and...


01 Dec, 2014, 07:00 ET Mylan Signs Agreement with Gilead to Enhance Access to Tenofovir Alafenamide (TAF)-based HIV Treatments in Developing Countries

 Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited has entered into an agreement with Gilead Sciences,...


25 Nov, 2014, 07:30 ET Mylan Confirms First-to-File Patent Challenge Relating to BREVIBLOC®

Mylan Inc. (Nasdaq: MYL) today confirmed that it and several subsidiaries have been sued by Baxter International, Inc., Baxter Healthcare...


05 Nov, 2014, 07:30 ET Mylan Launches Generic Loestrin 24 Fe®

Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous...


30 Oct, 2014, 16:05 ET Mylan Third Quarter 2014 Adjusted Diluted EPS Increases 41% to $1.16

 Mylan Inc. (Nasdaq: MYL) today announced its financial results for the three and nine months ended September 30, 2014. Third Quarter...


30 Oct, 2014, 12:48 ET Mylan Launches Generic Viramune XR®

Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Nevirapine Extended-release tablets, 400 mg, which is the generic version of...


06 Oct, 2014, 07:30 ET Mylan Launches Generic Combivir®

 Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Lamivudine and Zidovudine Tablets USP, 150 mg/300 mg, which is the...